Ultragenyx: Q2 Earnings Snapshot

Associated Press Finance
1 min read
0
In this article:

NOVATO, Calif. (AP) — NOVATO, Calif. (AP) — Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $159.8 million in its second quarter.

On a per-share basis, the Novato, California-based company said it had a loss of $2.25.

The results fell short of Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $2.11 per share.

The biotechnology company posted revenue of $108.3 million in the period, beating Street forecasts. Eight analysts surveyed by Zacks expected $105.2 million.

Ultragenyx expects full-year revenue in the range of $425 million to $450 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE

Advertisement

Recommended Stories